Capsida Biotherapeutics
Latest round
- Series A
Last raised
- Apr 2021
Total raised
- $50M
Investors
- 2
About Capsida Biotherapeutics
Capsida Biotherapeutics, Inc.Founded in 2019, Capsida Biotherapeutics, Inc. is a biopharmaceutical company based in the US, specializing in gene therapy innovations. The company was founded by Viviana Gradinaru, who has a background in neuroscience and previously contributed to research in gene delivery systems.Capsida Biotherapeutics specializes in developing targeted, intravenous (IV) gene therapies aimed at treating both rare and more common diseases. Their core offerings include investigational therapies for STXBP1 Developmental and Epileptic Encephalopathy (STXBP1-DEE), Parkinson’s Disease associated with GBA mutations (PD-GBA), and Friedreich’s Ataxia (FA). These therapies employ proprietary engineered capsids designed for high transduction levels in specific tissues, minimizing interactions with non-target organs.Capsida Biotherapeutics operates on a B2B model, partnering with leading biopharmaceutical companies to co-develop and commercialize its gene therapies. Revenue is anticipated through strategic collaborations with firms such as AbbVie, CRISPR Therapeutics, and Lilly’s Gene Therapy Division, alongside potential milestone payments and royalties.Capsida Biotherapeutics plans to enhance its product pipeline and expand its market reach.00 mn will facilitate the opening of a new manufacturing facility, supporting the development of new therapies. The company aims to design and launch additional products targeting unmet medical needs in various regions, with a focus on North America and potentially other global markets in the coming years.
Who invested in Capsida Biotherapeutics
2 investors across 1 round
See all investors in Capsida Biotherapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Apr 29, 2021
Amount
$50M
Investors
Questions about Capsida Biotherapeutics
Who invested in Capsida Biotherapeutics?
Capsida Biotherapeutics has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Capsida Biotherapeutics raised?
Capsida Biotherapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Capsida Biotherapeutics last raise money?
Capsida Biotherapeutics's most recent round on record is a Series A, in Apr 2021.
What does Capsida Biotherapeutics do?
Capsida Biotherapeutics is a biotechnology company.
Where is Capsida Biotherapeutics headquartered?
Capsida Biotherapeutics is headquartered in US.
Which VCs invest in companies like Capsida Biotherapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Capsida Biotherapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Capsida Biotherapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.